Earnings Call · Q1 FY2026·2026-05-06

Q1 26EPS -28.57%·Rev n/aQ4 25EPS +39.09%·Rev n/aQ3 25EPS +20.00%·Rev n/aQ2 25EPS +10.00%·Rev n/a⚠ consensus missing

Trevi Therapeutics, Inc. TRVI

Jennifer Good — President & CEO

David Hastings — Chief Financial Officer

−2.7%1d on move date−4.1% vs SPY3d−1.1%5d+0.7%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TRVI calls or request research access.

More TRVI calls Browse calls Request research access